Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer

• Type of Material: Article
• Authors: Agreen Hadadi, Emory University; Katherine ER Smith, Emory University; Limeng Wan, Emory University; Jacqueline R Brown, Emory University; Greta Russler, Emory University; Lauren Yantorni, Emory University; Sarah Caulfield, Emory University; Jennifer Lafollette, Grady Memorial Hospital; Melvin Moore, Emory University; Omer Kucuk, Emory University; Bradley Carthon, Emory University; Bassel Nazha, Emory University; Yuan Liu, Emory University; Mehmet Bilen, Emory University
• Language: English
• Date: 2022-05-12
• Publisher: ELSEVIER SCIENCE INC
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2022 Elsevier Inc. All rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.urolonc.2022.03.016
• Title of Journal or Parent Work: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
• Volume: 40
• Issue: 6
• Start Page: 271.e9
• End Page: 271.e18
• Grant/Funding Information: This work was supported by National Institutes of Health/ National Cancer Institute and the Biostatistics and Bioinformatics Shared Resource of the Winship Cancer Institute of Emory University under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
• Keywords: Biomarkers; Basophils; Life Sciences & Biomedicine; SCORE; Hormone-sensitive prostate cancer; Oncology; INFLAMMATION; Basophil to lymphocyte ratio; Science & Technology; SURVIVAL; Urology & Nephrology; Castration-sensitive prostate cancer

Abstract

Background: Biomarkers have the potential to provide clinical guidance, but there is limited data for biomarkers in metastatic hormone sensitive prostate cancer (mHSPC). Methods: We performed a retrospective multicenter review from Winship Cancer Institute at Emory University and Georgia Cancer Center for Excellence at Grady Memorial Hospital (2014–2020) in the United States of America (USA). We collected demographics, disease characteristics, and laboratory data, including complete blood counts (CBC) at the start of upfront therapy. We evaluated overall survival (OS) and progression-free survival (PFS) associated with baseline lab values. Results: 165 patients were included with a median follow-up time of 33.5 months (mo). 105 (63.6%) had Gleason scores of 8-10 and 108 (65.9%) were classified as high-volume disease. 92 patients received upfront docetaxel (55.8%) and 73 received upfront abiraterone (44.2%). Univariate analyses (UVA) and multivariable analyses (MVA) identified worse clinical outcomes (CO) associated with elevated basophils and basophil-to-lymphocyte ratio (BLR). Based on MVA, elevated basophils (defined as ≥0.1, optimal cut) were associated with a hazard ratio (HR) of 3.51 (95% CI 1.65–7.43, P 0.001) for OS and HR of 1.88 (95% CI 1.05-3.38, P 0.034) for PFS. Our MVA also found that BLR ≥0.0142 was associated with HR 2.11 (95% CI 1.09–4.10, P 0.028) for OS; however, PFS was not statistically significant. Conclusion: We conclude that elevated baseline basophils and BLR are associated with worse clinical outcomes in mHSPC. Although results require further validation, BLR is a potential prognostic biomarker.